We found that while GrB treatment decreased cAMP level, pretreatment with SCH significantly dose-dependently attenuated the effect with complete blockage at the highest dosage, confirming the role of GrB-PAR-1 interactions in mediating these effects (Figure 2C). The gene discussed is GZMB; the disease is spindle cell hemangioma.